The oligonucleotide synthesis services at Aurigene is supported by a state-of-the-art lab facility and skilled scientists with expertise in various types of oligos. We have an in-house custom synthesis of phosphoramidites and the ability to perform complex conjugation using click chemistry, amide coupling and thiol mediated C-S & S-S bond.
Our dedicated lab space of 1000 sq.ft is equipped with humidity control. Aurigene’s oligonucleotide platform is supported by trained team that helps optimize the designed oligonucleotide along with primary assay iterations. We have the ability to synthesize 10-40-mer oligonucleotide up to 1-gram scale. We perform all standard modifications, with or without backbone modification, for which phosphoramidites are made in-house and also available commercially. Oligo equipments at Aurigene: K and A H-16 automated DNA/RNA synthesizer AKTA pure 25M FPLC purification system Sartoflow smart TFF system for concentration and desalting Martin Christ LSC plus lyophilizer with lyocube, benchtop tray lyophilizer Agilent LC-MS for oligonucleotide analysis Implen N60 nano spectrophotometer
Complex conjugation using click chemistry, amide coupling and thiol mediated C-S & S-S bond
Ion exchange and reverse phase HPLC
Expertise in nucleoside, sugar modifications, base modifications
State-of-the-art drug discovery facility using oligonucleotide modality
Synthesis between 10-40-mer oligonucleotide
In-house custom phosphoramidite synthesis
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
Oligonucleotides can be synthesized using solid-phase (Peptides) and one pot liquid phase (enzymatic) method in the lab for milligram to multi-kilogram scale. Steps involved in solid-phase Oligo synthesis are detritylation, coupling, oxidation and capping. One-pot liquid phase oligo synthesis requires polymerase enzyme, template oligonucleotide and nucleotide triphosphate as starting materials.
Accuracy of chemical synthesis of Oligonucleotides is maintained by maintaining the order of starting materials used during the synthesis process.
Oligonucleotide drugs help modulate the effect of a disease-causing gene by targeted degradation/activation of gene expression or gene editing. This activity may cause the disease to be controlled or cured.
Oligos are stable for 6 weeks in buffer when stored at 37°C and for long-term stability is to be stored between -20°C to -80°C. During storage, oligos should not be exposed to direct sunlight or UV rays.
We can Synthesis 10-40-mer oligonucleotide up to 1 gram scale.
We can perform all standard modifications, with or without backbone modification, for which Phosphoramidites are commercially available. We also have the capabilities of making any customized Phosphoramidite in-house.
For a period of 6 weeks, Oligos can be stored in T10E1 buffer at 37°C and for the long term, Oligonucleotides can be dried down and stored with or without TE buffer at -20°C.
Typical Oligonucleotide synthesis does not produce phosphate on the 5’ or 3’ end. On request, oligonucleotides can be synthesized with phosphate on the 5’ or 3’ end.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.